Terms: = Liver cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Prognosis
73 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
3. Anti-cancer activity and cellular uptake of 7,3',4'- and 7,8,4'-trihydroxyisoflavone in HepG2 cells under hypoxic conditions.
Tzeng WS; Teng WL; Huang PH; Yen FL; Shiue YL
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2288806. PubMed ID: 38153119
[TBL] [Abstract] [Full Text] [Related]
4. Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract] [Full Text] [Related]
5. Construction and validation of a immune-related prognostic gene DHRS1 in hepatocellular carcinoma based on bioinformatic analysis.
Xu S; Wang W; Meng T; Wang F; Wang G; Huang F; Wang G; Yu X; Wu R; Hou L; Ye Z; Zhang X; Zhao H; Shen Y
Medicine (Baltimore); 2023 Oct; 102(42):e35268. PubMed ID: 37861541
[TBL] [Abstract] [Full Text] [Related]
6. In vivo self-assembly and delivery of vegfr2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.
Yu L; Fan G; Wang Q; Zhu Y; Zhu H; Chang J; Wang Z; Zhan S; Hua X; She D; Huang J; Wang Y; Zhao J; Zhang CY; Chen X; Zhou G
Cell Death Dis; 2023 Sep; 14(9):626. PubMed ID: 37739958
[TBL] [Abstract] [Full Text] [Related]
7. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
Xu S; Dong K; Gao R; Yang Y; Zhou Y; Luo C; Chen W; Liu SM
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12249-12263. PubMed ID: 37434092
[TBL] [Abstract] [Full Text] [Related]
8. Histological markers, sickle-shaped blood vessels, myxoid area, and infiltrating growth pattern help stratify the prognosis of patients with myxofibrosarcoma/undifferentiated sarcoma.
Washimi K; Kasajima R; Shimizu E; Sato S; Okubo Y; Yoshioka E; Narimatsu H; Hiruma T; Katayama K; Yamaguchi R; Yamaguchi K; Furukawa Y; Miyano S; Imoto S; Yokose T; Miyagi Y
Sci Rep; 2023 Apr; 13(1):6744. PubMed ID: 37185612
[TBL] [Abstract] [Full Text] [Related]
9. Primary and secondary angiosarcomas of the liver: a multi-institutional study of 32 cases.
Liao X; Lai J; Lin J; Zhang D
Hum Pathol; 2023 Jul; 137():10-17. PubMed ID: 37054784
[TBL] [Abstract] [Full Text] [Related]
10. A subset of vegfr-TKIs activates AMPK in LKB1-mutant lung cancer.
Yang L; Zhang Q; Xiong Y; Dang Z; Xiao H; Chen Q; Dai X; Zhang L; Zhu J; Wang D; Li M
Cancer Sci; 2023 Apr; 114(4):1651-1662. PubMed ID: 36459496
[TBL] [Abstract] [Full Text] [Related]
11. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract] [Full Text] [Related]
12. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.
Chen Y; Qiu X; Wu D; Lu X; Li G; Tang Y; Jia C; Xiong Z; Wang T
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140703
[TBL] [Abstract] [Full Text] [Related]
13. The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis.
Muraishi N; Kawamura Y; Akuta N; Shindoh J; Matsumura M; Okubo S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Yasuda I; Kumada H
Oncology; 2023; 101(2):134-144. PubMed ID: 36103864
[TBL] [Abstract] [Full Text] [Related]
14. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition.
Li R; Okada H; Yamashita T; Nio K; Chen H; Li Y; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955438
[TBL] [Abstract] [Full Text] [Related]
15. The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma.
Li J; Zhang X; Yao L; Hu K
Aging (Albany NY); 2022 May; 14(10):4513-4529. PubMed ID: 35622386
[TBL] [Abstract] [Full Text] [Related]
16. CCDC88A Post-Transcriptionally Regulates VEGF
Hu Q; Li Y; Chen H; Liao H; He Y; Zheng Q
Front Immunol; 2022; 13():859331. PubMed ID: 35493459
[TBL] [Abstract] [Full Text] [Related]
17. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2022 Jun; 89(6):761-772. PubMed ID: 35445315
[TBL] [Abstract] [Full Text] [Related]
18. BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
Chen H; Nio K; Tang H; Yamashita T; Okada H; Li Y; Doan PTB; Li R; Lv J; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163396
[TBL] [Abstract] [Full Text] [Related]
19. Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.
Song J; Guan Z; Song C; Li M; Gao Z; Zhao Y
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846786
[TBL] [Abstract] [Full Text] [Related]
20. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating vegfr-2 signaling pathway in hepatocellular carcinoma.
Teng F; Zhang JX; Chang QM; Wu XB; Tang WG; Wang JF; Feng JF; Zhang ZP; Hu ZQ
J Exp Clin Cancer Res; 2020 Nov; 39(1):235. PubMed ID: 33168027
[TBL] [Abstract] [Full Text] [Related]
[Next]
